Skip to main content
Premium Trial:

Request an Annual Quote

Gene Editing Shop Recombinetics Surpasses $2M Fundraising Goal

NEW YORK (GenomeWeb News) – Gene editing firm Recombinetics today said that it surpassed its $2 million fundraising goal this month.

The St. Paul, Minn.-based firm did not disclose its investors.

Founded in 2008, Recombinetics is using a gene editing technology called TALENs to produce its first biomedical product and to develop the first agricultural products, it said on its website.

TALENs are sequence-specific DNA scissors that can be custom engineered to target and modify any gene of interest in any species.

Recombinetics has secured $3.4 million in private investments since its founding. It also has brought in $1.5 million in development program funding through contracts with the animal agriculture industry, grants from the US Department of Agriculture, and contracts with the National Institutes of Health, the company said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.